By Jason Derry —

Advanced Cell Technology, Inc. has announced that it will acquire Mytogen, Inc., which has completed a Phase I clinical trial relating to its Myoblast Program for treating heart failure.  The Myoblast Program is a stem cell therapy approach to treating a patient having heart failure, in which autologous myoblasts are obtained from the patient, expanded for two to three weeks, and transplanted back into the patient’s heart.  Mytogen has been given permission from the FDA to proceed to Phase II trials.  Advanced Cell Technology, which recently announced that it has successfully derived a human embryonic stem cell line without destroying an embryo, is focused on using stem cell technology in the field of regenerative medicine.

Jason Derry, Ph.D., who graduated with honors from DePaul University
College of Law, is a molecular biologist and founding author of Patent Docs.